Objective
ASCLEPIUS’s overall aim is to boost the scientific excellence and innovation capacity of Giorgi Eliava Institute of Bacteriophagy, Microbiology and Virology (Eliava) and its high-quality Twinning partners - l’Institut national de recherche pour l’agriculture, l’alimentation et l’environnement, Universidade do Minho and Intelligentsia Consultants Sarl – to expand their insights in phage therapy for treating Pseudomonas aeruginosa and Staphylococcus aureus. To achieve this aim, ASCLEPIUS will implement a research and innovation strategy over three years based upon five objectives:
Objective 1: Conduct exploratory research on phage therapy for treating Pseudomonas aeruginosa and Staphylococcus aureus.
Objective 2: Transfer knowledge between experienced researchers of Eliava and the Twinning partners.
Objective 3: Enhance career prospects of early-stage researchers of Eliava and the Twinning partners.
Objective 4: Improve Eliava’s management and administrative capacity for European R&D programmes.
Objective 5: Raise the research profile of Eliava and the Twinning partners.
Programme(s)
Funding Scheme
HORIZON-CSA - HORIZON Coordination and Support ActionsCoordinator
0160 Tbilisi
Georgia